- Home
- VKTX
as 12-20-2024 4:00pm EST
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 4.6B | IPO Year: | 2015 |
| Target Price: | $106.75 | AVG Volume (30 days): | 3.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.23 - $99.41 | Next Earning Date: | 02-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Viking Therapeutics Inc. (VKTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MACARTNEY LAWSON | VKTX | Director | Nov 8 '24 | Sell | $68.67 | 2,000 | $137,333.40 | 47,965 | |
| ZANTE GREG | VKTX | Chief Financial Officer | Oct 28 '24 | Sell | $78.19 | 131,687 | $10,089,164.06 | 150,572 | |
| SINGLETON J MATTHEW | VKTX | Director | Oct 25 '24 | Sell | $79.50 | 16,000 | $1,272,000.00 | 9,500 | |
| Rouan Sarah Kathryn | VKTX | Director | Oct 25 '24 | Sell | $80.89 | 11,000 | $889,790.00 | 0 |
Latest Viking Therapeutics Inc. News
VKTX Breaking Stock News: Dive into VKTX Ticker-Specific Updates for Smart Investing
Investor's Business Daily
7 hours ago
Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.
Motley Fool
11 hours ago
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
MT Newswires
14 hours ago
Amgen, Eli Lilly, Viking Therapeutics Shares Rise Pre-Bell After Novo Nordisk's Obesity Treatment Falls Short of Expectations
Investor's Business Daily
14 hours ago
Novo Crashes 20% After New Obesity Drug Misses Forecasts. Lilly, Viking, Amgen Jump.
Zacks
2 days ago
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug
Simply Wall St.
2 days ago
Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
Zacks
2 days ago
Here's Why VKTX Stock Plummeted 18% on Wednesday
Investor's Business Daily
2 days ago
Viking Plummets After Merck Inks A $2.01 Billion Obesity Deal — With Someone Else
Compare VKTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VKTX Viking Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.